Archive

Posts tagged under: investigators

Find medical experts on the go with ta-Scan Podium

With ta-Scan Podium, our new semantic search application, MDCPartners is going mobile. ta-Scan Podium allows you to leverage the powerful search capabilities of ta-Scan’s clinical intelligence database to find Key External Experts on the go, using any tablet device.

If you are moving into a new disease area or if you are trying to identify new therapeutic experts in an existing indication, why remain limited to the endless number of databases, only available on your desktop? Whether you’re at your desk, at a meeting or a conference, you can now search, refine, save, and share any expert profile with a few simple clicks on your tablet.

Learn more about Podium in the video below and see how it can improve your work effectiveness.
Book your free demo using the following link → https://www.ta-scan.com/podiumdemo

Meet David Cocker at DIA 2017 and discover the new ta-Scan mobile app!

MDCPartners’ CSO David Cocker will be attending the DIA 2017 meeting in Chicago on June 18-22 to showcase ta-Scan‘s new mobile app.

About DIA 2017

The Drug Information Association, a non-profit association, is the only global organization dedicated to bringing health care product development professionals together in a trusted, global, neutral environment to share insights and drive action in health care product development and life cycle management.

ta-Scan Mobile App

ta-Scan now has its own mobile app! Have a look at the video below: it’s a little demo on how it works. This tool enables MSLs to search for high ranking investigators on the go. Clinical business intelligence is now truly at your fingertips.

Meet us in Chicago

Book an appointment now to connect with David Cocker in Chicago.

We look forward to seeing you in Chicago!

Curious about what to expect at ASCO 2017? ta-Scan has you covered!

As ASCO 2017 kicks off this Friday, finding the information relevant to you can be a hassle. Using ta-Scan, you can quickly uncover key information about sponsors, clinical trials, drugs and investigators contributing to ASCO this year. To help you out, we highlight a few interesting points.

asco 2017 abstracts

Abstracts

Over the past 3 years, there have been some notable changes in therapeutic areas discussed at the American Society of Clinical Oncology’s annual meeting. It comes as no surprise that the Immune Oncology trend is growing year on year, much like Lung Cancer. On the other hand, interest in Breast Cancer is steadily declining, which could be due to the disappointing results of Immune Oncology within Breast Cancer. Another interesting fact is the gain in Gastrointestinal Cancer abstracts at this year’s conference, after a relatively quiet 2016.

asco 2017 abstracts ta distribution

Sponsor & trial activity

Of the 1,203 clinical trials that are cited at ASCO 2017, 6 key commercial sponsors have seen considerable fluctuations in trial activity when compared to ASCO 2016. Significant gains can be seen in the trial activity of BMS, Pfizer, and Roche, whereas Novartis, Sanofi, and Johnson & Johnson have seen a decrease in trial numbers.

asco 2017 abstracts ta distribution

ta-Scan’s top 5 drugs to watch at ASCO 2017

With preliminary results already disclosed for some drugs debuting at ASCO, ta-Scan highlights some new drugs being discussed in the Immune Oncology space. Introduction of two Antibody drug conjugates for Prostate and Breast Cancer, the Colony Stimulating Factor-1 receptor Cabiralizumab and CD122 compounds from Nektar that facilitate immune response against tumors. In addition to anti-PD-L1 compound Incyte have a promising combination with Pembrolizumab and an indolamine 2,3 dioxygenase inhibitor, Epacadostat.

asco 2017 abstracts pd-pd-l

Investigator & sponsor collaborations

Looking at the percentage of top Oncology experts used by the leading commercial sponsors of trials talked about at ASCO 2017, it’s clear that Roche and Merck have an evenly distributed usage of investigators in both the USA as well as Europe, whereas others seem to lean toward USA investigator preference.

asco 2017 abstracts top oncology investigators

ta-Scan’s top 5 drugs to watch at ASCO 2017

With preliminary results already disclosed for some drugs debuting at ASCO, ta-Scan highlights some new drugs being discussed in the Immune Oncology space. Introduction of two Antibody drug conjugates for Prostate and Breast Cancer, the Colony Stimulating Factor-1 receptor Cabiralizumab and CD122 compounds from Nektar that facilitate immune response against tumors. In addition to anti-PD-L1 compound Incyte have a promising combination with Pembrolizumab and an indolamine 2,3 dioxygenase inhibitor, Epacadostat.

asco 2017 abstracts new drugs

Learn more about ta-Scan

Interested in ta-Scan‘s analytical services? Request your free webinar here or contact us.

Categories

 

Tags

 

Connect with MDCPartners

Follow us on LinkedIn

Follow us on Twitter

Top of Page